New GLP-1 Pill Foundayo (Orforglipron) Gets FDA Approval for Obesity
A new daily weight-loss pill called orforglipron could help solve one of the biggest problems linked to popular GLP-1 weight-loss drugs like Wegovy and Mounjaro — regaining weight after stopping treatment.
Weight-loss injections have changed obesity treatment worldwide. In Great Britain alone, nearly 1.6 million adults have reportedly used weight-loss medications over the past year. These drugs help many people lose significant weight and improve health conditions like high blood pressure, cholesterol, and blood sugar levels.
However, there’s a major downside.
Studies show that many patients regain much of the lost weight once they stop taking the injections. At the same time, the health benefits also begin to disappear.
Another challenge is cost. In the UK, Mounjaro can cost around £300 per month through private prescriptions, making long-term treatment difficult for many people to afford.
Why Current Weight-Loss Drugs Are Expensive
Most current GLP-1 drugs are made from peptides, which are small proteins that break down quickly in the digestive system. Because of this, they must be given through injections instead of pills.
These injector pens are costly to manufacture and must also be stored in refrigerators, increasing overall expenses.
That’s where orforglipron may offer a big advantage.
What Makes Orforglipron Different?
Orforglipron, sold under the brand name Foundayo, was recently approved by the US Food and Drug Administration (FDA) for obesity treatment.
Unlike injectable GLP-1 drugs, orforglipron is a small-molecule pill. This means it can survive digestion and be taken orally once a day.
Small-molecule medicines are generally much cheaper and easier to produce. Common medications like aspirin and ibuprofen also fall into this category.
Because of this simpler production process, orforglipron could make weight-loss treatment more affordable and accessible for millions of people.
In the United States, a month’s supply is expected to cost between US$149 and US$299, compared with more than US$1,000 per month for Mounjaro.
How Effective Is the New Pill?
Clinical trials show that orforglipron helped adults with obesity lose slightly more than 15% of their body weight on average.
That result is similar to Wegovy, although still lower than the roughly 21% weight loss seen with Mounjaro.
But researchers say the most exciting finding may be its ability to help people keep the weight off after stopping injections.
Could This Pill Help Prevent Weight Regain?
A recent study tested whether people who had already lost weight using Wegovy or Mounjaro could maintain their progress by switching to orforglipron.
The trial involved patients who had lost at least 5% of their body weight over 72 weeks while using injectable GLP-1 drugs.
After stopping their injections, participants were given either orforglipron or a placebo pill for another 52 weeks.
The results were promising.
Among former Mounjaro users:
- People taking placebo regained more than 50% of the lost weight
- Those taking orforglipron regained only 26%
Among former Wegovy users:
- Placebo users regained 62% of lost weight
- Orforglipron users regained only 21%
Researchers also found that people taking orforglipron continued to show improvements in:
- Blood sugar
- Blood pressure
- Cholesterol
- Insulin levels
Why This Matters
Keeping weight off is often the hardest part of any weight-loss journey.
While the study was relatively small, involving just over 100 participants per group, experts believe it points toward a potentially important future strategy:
using lower-cost oral medication to maintain long-term weight loss after injectable treatment.
This could reduce costs for patients while helping them continue benefiting from improved health.
When Will Orforglipron Be Available?
Orforglipron has not yet been approved for weight loss in the UK.
If approved by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), experts expect it could become available between late 2026 and early 2027.
For many people struggling with obesity, this new pill may represent a more affordable, convenient, and sustainable way to manage long-term weight loss.
#WeightLoss #GLP1 #ObesityTreatment #Wegovy #HealthNews